Targets to treatmetabolic syndrome in polycystic ovary syndrome

被引:57
作者
Mahalingaiah, Shruthi [1 ]
Diamanti-Kandarakis, Evanthia [2 ]
机构
[1] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA
[2] Univ Athens, Sch Med, Dept Diabet Endocrinol & Metab, Athens 11521, Greece
基金
美国国家卫生研究院;
关键词
group care; lifestyle modification; metabolic syndrome; polycystic ovary syndrome; CARDIOVASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE MODIFICATION; LOW-DENSITY-LIPOPROTEIN; GLYCATION END-PRODUCTS; GONADOTROPIN-RELEASING-HORMONE; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; OBESE WOMEN;
D O I
10.1517/14728222.2015.1101067
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Metabolic syndrome is comprised of a combination of the following states: increased insulin resistance, dyslipidemia, cardiovascular disease, and increased abdominal obesity. Women with polycystic ovary syndrome (PCOS) have an increased risk of developing metabolic syndrome over the course of their lives. Metabolic syndrome increases risk of major cardiovascular events, morbidity, quality of life, and overall health care costs. Though metabolic syndrome in women with PCOS is an area of great concern, there is no effective individual medical therapeutic to adequately treat this issue. Areas Covered: This article will review key aspects of metabolic syndrome in PCOS. We will discuss classic and novel therapeutics to address metabolic syndrome in women with PCOS. We will conclude with the importance of developing strategic interventions to increase the compliance to lifestyle and dietary modification, in addition to appreciation of the emerging pharmaceutical therapeutics available. Expert Opinion: Innovation in lifestyle modification, including diet, exercise, with and without dedicated stress reduction techniques is the future in treatment of metabolic syndrome in PCOS. Application of novel interventions, such as group medical care, may improve future adherence to lifestyle modification recommendations, in addition to or in combination with pharmaceutical therapeutics.
引用
收藏
页码:1561 / 1574
页数:14
相关论文
共 166 条
[1]   Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use [J].
Abdollahi, M ;
Cushman, M ;
Rosendaal, FR .
THROMBOSIS AND HAEMOSTASIS, 2003, 89 (03) :493-498
[2]  
Ajossa S, 2004, Minerva Ginecol, V56, P15
[3]   Efficacy of troglitazone on body fat distribution in type 2 diabetes [J].
Akazawa, S ;
Sun, FY ;
Ito, M ;
Kawasaki, E ;
Eguchi, K .
DIABETES CARE, 2000, 23 (08) :1067-1071
[4]   Thuja occidentalis L. and its active compound, α-thujone: Promising effects in the treatment of polycystic ovary syndrome without inducing osteoporosis [J].
Akkol, Esra Kupeli ;
Ilhan, Mert ;
Demirel, Murside Ayse ;
Keles, Hikmet ;
Tumen, Ibrahim ;
Suntar, Ipek .
JOURNAL OF ETHNOPHARMACOLOGY, 2015, 168 :25-30
[5]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[6]   Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome [J].
Apridonidze, T ;
Essah, PA ;
Iuorno, MJ ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :1929-1935
[7]   Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase [J].
Arlt, W ;
Auchus, RJ ;
Miller, WL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (20) :16767-16771
[8]   A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain [J].
Asunción, M ;
Calvo, RM ;
San Millán, JL ;
Sancho, J ;
Avila, S ;
Escobar-Morreale, HF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) :2434-2438
[9]   Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review [J].
Austin, MA ;
Hutter, CM ;
Zimmern, RL ;
Humphries, SE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (05) :407-420
[10]   Adrenal androgen excess in the polycystic ovary syndrome: Sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis [J].
Azziz, R ;
Black, V ;
Hines, GA ;
Fox, LM ;
Boots, LR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07) :2317-2323